Klaria Pharma Holding AB (publ)

Chart & Performance

D1W1MN

P/E

—

P/S

28.96

EPS

—

Div Yield, %

—

Shrs. gr., 5y

32.01%

Rev. gr., 5y

4.51%

Revenues

+300.36%

Net income

-39m

L-18.53%

CFO

-35m

L+193.57%

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Profile

Klaria Pharma Holding AB (publ.) functions as a pharmaceutical enterprise, active both in Sweden and across global territories. Its current portfolio features Sumatriptan for migraine management and Midazolam for combating acute epileptic seizures. Within its pipeline, Klaria is developing Epinephrine/Adrenaline to address severe allergic responses, Naloxone for reversing opioid overdoses, and Ketamine for applications in acute pain and mood disorders. Moreover, the company is actively involved in bringing cannabis/cannabinoid products, including THC and CBD, to market for medical and recreational purposes. Established in 2014, Klaria is headquartered in Uppsala, Sweden.

URL

https://www.klaria.com/

IPO date

Oct 21, 2015

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title SEK in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title SEK in thousands, except ratios and share amounts	2025‑12	2024‑12	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT